Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Zulresso

- PMLiVE

Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3

Biogen and Sage signed a $3.1bn deal last year to jointly develop potential depression therapies

- PMLiVE

Biogen signs $3.1bn deal with Sage for potential depression therapies

Zuranolone already has a breakthrough therapy designation from the US FDA

- PMLiVE

Sage slides off a MOUNTAIN as depression drug flunks trial

Share price drops 60% as investors react to news

- PMLiVE

Sage gets final US clearance for postpartum depression drug Zulresso

Controlled drug needs special REMS monitoring

- PMLiVE

Sage’s postpartum depression treatment Zulresso gains US approval

First approval of its kind

- PMLiVE

Sage surges after depression drug gets rapid path to approval

Will be able to file a marketing application based on its phase II trial

- PMLiVE

Otsuka refiles ‘digital’ medicine for mental illness

Soluble sensor tracks drug ingestion and shares information with HCPs

- PMLiVE

Otsuka and Lundbeck file Abilify follow-up in the US

Brexpiprazole to be reviewed for use in schizophrenia and major depressive disorder

- PMLiVE

Shire’s ADHD drug fails in depression trial

Company drops Vyvanse for use in major depressive disorder

- PMLiVE

Lilly depression drug fails late-stage trials

Will not pursue edivoxetine as an add-on treatment for depression

- PMLiVE

Pipeline: Major depressive disorder therapeutics

There are limited pipeline prospects to address this significant health issue

- PMLiVE

Lundbeck buoyed by Brintellix approval in US

FDA gives green light for to Cipralex/Lexapro successor in depression

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links